Experimental therapy for deadly brain tumor stalls after single patient
NCT ID NCT02742883
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 study tests two experimental drugs, atengenal and astugenal, in people with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. The trial aimed to enroll up to 100 participants across five age and treatment groups, but only 1 person joined before the study was suspended. The goal was to see if the drugs could shrink tumors or extend survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Antineoplaston therapy (atengenal and astugenal)
What this could lead to
If it works, this could point toward a treatment for DIPG, a rare and aggressive brain tumor in children.
What could go wrong
The trial is very early (phase 2), has only 1 participant, and is currently suspended. Antineoplaston therapy is controversial and not widely accepted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Burzynski Clinic
Houston, Texas, 77055-6330, United States